The clinical trial report, “Glioblastoma Multiforme (GBM) - Global Clinical Trials Review, 2026" provides an overview of Glioblastoma Multiforme (GBM) Clinical trials scenario. This report provides top line data relating to the clinical trials on Glioblastoma Multiforme (GBM). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Glioblastoma Multiforme (GBM)
- Apr 21, 2026: Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
- Apr 21, 2026: Immunoscape Presents Data on Significant, Selective In-Vivo Expansion of Cell Therapy Product at Aacr Annual Meeting
- Apr 17, 2026: New Data Demonstrates the Unique Scalability of Evaxion’s Ai-Immunology Platform in Glioblastoma
- Apr 08, 2026: Trogenix Announces Publication of Pre-Clinical Data in Nature Demonstrating Complete Tumour Eradication and Protection in Aggressive Brain Cancer
- Mar 24, 2026: Myosin Therapeutics Awarded Florida Cancer Innovation Fund Grant to Support STAR-GBM Clinical Trial
- Mar 24, 2026: Northwest Biotherapeutics Gains Positive Outlook with Innovative Therapy
- Mar 18, 2026: Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR and ANN 2026
- Mar 18, 2026: Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR and AAN 2026
- Mar 17, 2026: Verismo to Present KIR-CAR Data - Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidate SynKIR-310 - at AACR Annual Meeting 2026
- Mar 17, 2026: Sprint Bioscience reports positive results from the VRK1 program
- Mar 17, 2026: Verismo to Present KIR-CAR Data - Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidate SynKIR-410 - at AACR Annual Meeting 2026
- Feb 27, 2026: Elicera Therapeutics Provides Update on Preclinical CAR T-Cell Program ELC-401 for Glioblastoma: Preclinical Development Concluded
- Feb 25, 2026: Gibson Oncology, NIH to Begin Phase 2 Trials of LMP744 for Treatment of First-Time Recurrent Glioblastoma
- Feb 17, 2026: Diakonos Oncology Announces Study to Continue after First DSMB Safety Review of DOC1021 in Phase 2 GBM Study
- Clinical Trial Profile Snapshots
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Disclaimer
- Source
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck & Co Inc
- Bristol-Myers Squibb Co
- Novartis AG
- Pfizer Inc
- AstraZeneca Plc
- Roche Holding AG
- NovoCure Ltd
- Eli Lilly and Co
- IQVIA Holdings Inc
- Thermo Fisher Scientific Inc
